Search
Search Constraints
You searched for: Author/Creator Radonjic, DejanLimit your search
- Radonjic, Dejan [remove] 3
- 616.99424 3
- Electronic journals 3
- Lung Neoplasms -- Abstracts 3
- Lung Neoplasms -- Periodicals 3
- Lungs -- Cancer 3
- Lungs -- Cancer -- Periodicals 3
- Periodicals 3
- Poumons -- Cancer -- Périodiques 3
- Ab antibody -- ABC atezolizumab, bevacizumab and chemotherapy combination -- ANG2 angiopoietin 2 -- APC antigen-presenting cells -- αPD-1 anti-programmed cell death protein 1 -- αPD-L1 anti-programmed death ligand-1 -- Arg1 arginase 1 -- β2M beta-2 microglobulin -- CCL C-C-motif chemokine ligand -- CI confidence interval -- CSF1 macrophage colony-stimulating factor 1 -- CTL cytotoxic T lymphocyte -- CTLA-4 cytotoxic T-lymphocyte antigen 4 -- CXCL12 C-X-C-motif chemokine ligand 12 -- DC dendritic cell -- DCR disease control rate -- EC endothelial cell -- ESMO European Society of Medical Oncology -- FASL Fas ligand -- GM-CSF granulocyte–macrophage colony-stimulating factor -- HLA human leukocyte antigen -- IDO indolaimine-2, 3-deoxygenase -- IFN interferon -- IL interleukin -- JAK Janus kinase -- LAG3 lymphocyte activation gene 3 -- M2 Mɸ type II macrophage -- MDSC myeloid-derived suppressor cell -- MHC major histocompatibility complex -- NF-κB nuclear factor kappa B -- NSCLC non-small cell lung cancer -- ORR objective response rate -- OS overall survival -- PD-1 programmed cell death protein 1 -- PD-L1 programmed death ligand-1 -- PD-L2 programmed death ligand-2 -- PFS progression-free survival -- PGE2 prostaglandin E2 -- PS performance status -- RECIST Response Evaluation Criteria in Solid Tumors -- STAT signal transducer and activator of transcription -- TAM tumor-associated macrophage -- TCR T-cell receptor -- TEM effector memory T cell -- TGFβ tumor growth factor beta -- TGR tumor growth rate -- TIM3 T-cell immunoglobulin and mucin domain-3 -- TME tumor microenvironment -- TNF tumor necrosis factor -- Treg regulatory T cell -- VEGF vascular endothelial growth factor -- VEGFR vascular endothelial growth factor receptor -- VISTA V-domain immunoglobulin suppressor of T-cell activation 1
- Adenocarcinoma -- Angiogenesis inhibitors -- Carcinoma -- Non-small cell lung -- Immunotherapy -- Observational study -- Prospective studies -- Treatment outcome 1